Drugs / Sanhuang Jingshiming
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07269769 | Apr 2026 → Dec 2031 expected | — | Tasly Pharmaceutical Group Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sanhuang Jingshiming | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07269769 ↗ |
| Known as | Sanhuang Jingshiming Pills | “The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.” NCT07269769 ↗ |